Updated bowel disease treatment summaries published by intelog

Updated quick-reference summaries of the latest NICE guidance on the management of Crohn's disease and ulcerative colitis can be found on the intelog website.

Summaries of the latest NICE guidance on Crohn's disease and ulcerative colitis are available on mims.co.uk
Summaries of the latest NICE guidance on Crohn's disease and ulcerative colitis are available on mims.co.uk

NICE now advises that a topical aminosalicylate should be the first-line approach for inducing remission in all patients with mild-to-moderate ulcerative colitis, with the addition of an oral aminosalicylate in cases of extensive disease or if remission is not achieved after 4 weeks.

If treatment with topical or oral corticosteroids is needed, the new guidance states this should be time-limited (ie, 4 to 8 weeks).

For patients with Crohn's disease, there are new recommendations on maintaining remission after surgery. These apply only to patients with ileocolonic disease who have had complete macroscopic resection within the last 3 months and who have no active residual disease (previously, the recommendations applied to everyone with adverse prognostic factors after surgery).

The updated recommendations for both forms of inflammatory bowel disease are summarised in separate quick-reference intelog summaries available online.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in